Me (OTC:MEHCQ) faces a second auction after a $305M bid challenges Regeneron's (REGN) initial bid for its assets. Read more ...

A key decision by the bankruptcy judge could help with protecting consumer data, write Diane Lourdes Dick and Anya Prince.

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

Me is proposing to reopen its bankruptcy auction to entertain a final offer from a nonprofit operated by its co-founder, ...

After a brief court dispute, 23andMe and all its assets are up for auction once again. The second time around, former CEO Amy ...

The move marks a turning point in 23andMe’s tumultuous decline. Founded in 2006 by Wojcicki, the company initially gained traction with its saliva-based ancestry kits and went public in 2021. By the ...

Regeneron Pharmaceuticals has promised to comply with 23andMe's existing privacy polices while also using data to fuel drug ...

The proposed transaction with Regeneron includes 23andMe’s personal genome service and total health and research services.

Recently, Regeneron ( REGN -1.41%) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its ...

Me has a path to a higher purchase price than the $256 million offered by biotech giant Regeneron after the genetic-testing ...

In trying to lead before the system could follow, 23andMe outpaced the very guardrails that might have legitimized it”: A ...

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...